SOD1

Chr 21ADAR

superoxide dismutase 1

Also known as: ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP, hSod1, homodimer

The protein functions as a cytoplasmic homodimer that converts superoxide radicals to molecular oxygen and hydrogen peroxide by binding copper and zinc ions. Mutations cause familial amyotrophic lateral sclerosis 1 and spastic tetraplegia with axial hypotonia through autosomal dominant and autosomal recessive inheritance patterns. The pathogenic mechanism involves dominant-negative effects where mutant protein disrupts normal cellular function.

GeneReviewsOMIMResearchSummary from RefSeq, OMIM, UniProt, Mechanism
MultiplemechanismAD/ARLOEUF 0.982 OMIM phenotypes
Clinical SummarySOD1
🧬
Gene-Disease Validity (ClinGen)
amyotrophic lateral sclerosis type 1 · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.31) despite low pLI — interpret in context.
📋
ClinVar Variants
189 unique Pathogenic / Likely Pathogenic· 90 VUS of 386 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — SOD1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.98LOEUF
pLI 0.177
Z-score 1.62
OE 0.31 (0.130.98)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.84Z-score
OE missense 0.75 (0.610.92)
65 obs / 87.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.31 (0.130.98)
00.351.4
Missense OE0.75 (0.610.92)
00.61.4
Synonymous OE1.28
01.21.6
LoF obs/exp: 2 / 6.4Missense obs/exp: 65 / 87.0Syn Z: -1.27
DN
0.73top 25%
GOF
0.4776th %ile
LOF
0.3941th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median · 1 literature citation
GOF1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNHarraz et al. (2008) concluded that certain SOD1 mutations exert a dominant-negative effect by interfering with normal SOD1/RAC1 interactions.PMID:18219391
GOFThus, we have argued that motor neuron disease is caused by gain-of-function mutations in the human SOD1 gene.PMID:8734301

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

386 submitted variants in ClinVar

Classification Summary

Pathogenic107
Likely Pathogenic82
VUS90
Likely Benign63
Benign19
Conflicting19
107
Pathogenic
82
Likely Pathogenic
90
VUS
63
Likely Benign
19
Benign
19
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
2
46
59
0
107
Likely Pathogenic
7
73
2
0
82
VUS
6
60
22
2
90
Likely Benign
0
0
35
28
63
Benign
0
0
19
0
19
Conflicting
19
Total1517913730380

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SOD1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Amyotrophic Lateral Sclerosis

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

RECRUITING
NCT07290062Phase PHASE1Insmed Gene Therapy LLCStarted 2026-01-09
INS1202
Amyotrophic Lateral Sclerosis

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

RECRUITING
NCT07223723Phase PHASE4BiogenStarted 2025-12-11
Tofersen
Transgender Individuals

Effects of Gender-Affirming Hormone Therapy on Cardiovascular, Metabolic, and Mental Health Outcomes in Transgender Adults.

NOT YET RECRUITING
NCT07394400Milagros Rocha BarajasStarted 2026-02-14
Amyotrophic Lateral Sclerosis

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

RECRUITING
NCT07259980BiogenStarted 2026-01-02
Tofersen
Rheumatoid ArthritisOsteoarthritisSarcopenia

Effect of Exercise Type on Muscle Quality in Patients With OA, SARC and RA: an Explorative Study

NOT YET RECRUITING
NCT06480643Phase NAAmsterdam UMC, location VUmcStarted 2024-12-01
High load exercise typeLow load exercise type
Amyotrophic Lateral Sclerosis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

RECRUITING
NCT06556394Phase PHASE1Ractigen Therapeutics.Started 2024-12-24
RAG-17Placebo
ALS (Amyotrophic Lateral Sclerosis)

Extended Study of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation

NOT YET RECRUITING
NCT07077668Phase EARLY_PHASE1Beijing Tiantan HospitalStarted 2025-07
A sterile aqueous solution of RAG - 17 preparation (sodium salt)
B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

RECRUITING
NCT05602194Phase PHASE3Children's Oncology GroupStarted 2023-08-14
Biospecimen CollectionCalaspargase PegolLevocarnitine
Amyotrophic Lateral Sclerosis

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

ACTIVE NOT RECRUITING
NCT06100276Phase PHASE1, PHASE2UniQure Biopharma B.V.Started 2024-08-01
AMT-162
ALS

Amyotrophic Lateral Sclerosis (ALS) Families Project

RECRUITING
NCT03865420Columbia UniversityStarted 2018-09-11
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

ACTIVE NOT RECRUITING
NCT04856982Phase PHASE3BiogenStarted 2021-05-17
TofersenPlacebo
Neurodegenerative DisordersParkinson DiseaseAlzheimer Disease

An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy

ENROLLING BY INVITATION
NCT06875739Fondazione Don Carlo Gnocchi OnlusStarted 2025-02-14
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM et al.·N Engl J Med
2022Clinical trial
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.
Miller TM et al.·JAMA Neurol
2026Clinical trial
Tofersen for SOD1 ALS.
Everett WH et al.·Neurodegener Dis Manag
2024Review
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller T et al.·N Engl J Med
2020Clinical trial
Top 5 results · since 2015Search PubMed ↗